Biogen has added a preclinical-stage drug candidate for Parkinson's disease via a $722.5 million licensing agreement with Alectos Therapeutic, as it continues to rebuild a pipeline behind its side ...

With the prospects for its Alzheimer’s drug aducanumab still up in the air, Biogen has moved to shore up its late-stage pipeline with a $3 billion licensing deal with Sage that adds drugs for ...

Recent business development deals have focused on enhancing the company’s late-stage pipeline, including the company’s latest collaboration with Stoke Therapeutics. In parallel, Biogen’s ...

Biogen faced several pipeline setbacks in 2024, including programs for ALS, tremor, and Angelman syndrome. Two promising late-stage programs, felzartamab entering Phase 3 trials for IgA ...

Biogen’s new CEO Christopher Viehbacher has wasted no time getting a pipeline re-prioritization underway while signaling that the formerly restrained company is ready to make some deals.

Jefferies downgraded Biogen from Buy to Hold, setting a new price target of $180, down from $250. Biogen faces potential earnings drop of 20-30% by 2030 due to Ocrevus biosimilar competition.

The analyst sees limited downside at current valuations and notes that continued pipeline progress, regulatory approvals, and a successful lecanemab launch could push the stock to around $350. Also ...